ASX ANNOUNCEMENT
6 July 2026

Chief Executive Officer Transition

Sydney, Australia, 6 July 2026: PainChek Ltd (ASX: PCK), developer of the world's first AI-powered pain assessment and monitoring application, advises that Philip Daffas will cease to serve as CEO and Managing Director effective immediately.

This is a planned transition to support PainChek's Financial Year 2027 strategy following FDA De Novo clearance. The Board and Mr Daffas have agreed that now is the right time for a change in leadership to accelerate PainChek's development of the US market.

The Board thanks Philip for his ten years of leadership as PainChek evolved from Australian research into the world's first AI-powered clinically validated pain assessment platform with operations in Australia, UK, NZ and North America.

During Philip's stewardship the company completed over 20 million clinical assessments, secured over 2,000 age care facilities and achieved FDA clearance.

The Board wishes Philip well in his next endeavours.

The Board advises that the process to appoint a new CEO is progressing. The Board expects to announce a new CEO in due course and will keep the market informed of any developments in accordance with its continuous disclosure obligation.

Mr Andy Hoggan will act as Interim CEO during this transition period. Andy is currently COO and has been a senior PainChek executive for six years. He has the full support of the Board.

This announcement has been approved for release by the Board.

For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

About PainChek
PainChek® is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.
Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, the United Kingdom and most recently FDA De Novo clearance in the United States.
PainChek® has contracts with over 2,000 aged care facilities, with more than 20,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

PainChek® is setting a new benchmark for pain assessment. Being the first TGA-approved and FDA-cleared medical device for pain assessment, PainChek® combines AI and Human Intelligence to detect pain in people who cannot reliably self-report.

For more information, visit: https://painchek.com